Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma

详细信息	查看全文 | 推荐本文 |

• 作者：Joong-Won Park¹ ; ^{jwpark@ncc.re.kr} ; Young Hwan Koh¹ ; Hyun Beom Kim¹ ; Hwi Young Kim¹ ; Sangbu An¹ ; Joon-Il Choi¹ ; Sang Myung Woo¹ ; Byung-Ho Nam²
• 关键词：TACE ; transarterial chemoembolization ; HCC ; hepatocellular carcinoma ; TTP ; time to progression ; BCLC ; Barcelona Clinic Liver Cancer ; VEGF ; vascular endothelial growth factor ; RECIST ; Response Evaluation Criteria in Solid Tumors ; CTCAE ; Common Terminology
• 刊名：Journal of Hepatology
• 出版年：2012
• 期刊代码：162_01688278
• 类别：med
• 出版时间：June, 2012
• 卷：56
• 期：6
• 页码：1336-1342
• 文件大小：838 K

摘要

| Figures/TablesFigures/Tables | ReferencesReferences

Background & Aims

Transarterial chemoembolization (TACE) is an important palliative treatment for unresectable hepatocellular carcinoma (HCC), but TACE-induced ischemic injury can upregulate angiogenic factors and is associated with poor prognosis. The aim of this study was to evaluate the safety and efficacy of concurrent conventional TACE and sorafenib in patients with unresectable HCC.

Methods

The primary objectives of this prospective, single-arm, phase II study were to evaluate safety and time to progression (TTP). Sorafenib was given 3 days after TACE and was administered for up to 24 weeks. Repeated TACE was performed on demand. Tumor response was assessed every 8 weeks.

Results

Fifty patients were treated and followed from July 2009 to May 2011. All patients were in Barcelona Clinic Liver Cancer (BCLC) stage B (82%) or C (18%). The median time of follow-up was 14.9 months and a median of 1 TACE session was given (range, 1-4). The median dose intensity of sorafenib was 68.7%(range, 37.3-100) of 800 mg daily. The most common reasons for dose reduction were hand-foot syndrome and thrombocytopenia. Thirty patients completed the study and 17 patients discontinued sorafenib due to disease progression. The overall median TTP was 7.1 months (95%confidence interval (CI), 4.8-7.5 months): 7.3 months in BCLC stage B; 5.0 months in BCLC stage C. The 6-month progression-free survival rate was 52%(95%CI, 37.3-66.1).

Conclusions

Concurrent treatment of unresectable HCC with conventional TACE and sorafenib demonstrates a manageable safety profile and a possibility of promising efficacy.